- Home
- GERN vs TXO Comparison
GERN vs TXO Comparison
Compare GERN & TXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- TXO
- Stock Information
- Founded
- GERN 1990
- TXO 2012
- Country
- GERN United States
- TXO United States
- Employees
- GERN N/A
- TXO N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- TXO Oil & Gas Production
- Sector
- GERN Health Care
- TXO Energy
- Exchange
- GERN Nasdaq
- TXO Nasdaq
- Market Cap
- GERN 823.0M
- TXO 788.9M
- IPO Year
- GERN 1996
- TXO 2023
- Fundamental
- Price
- GERN $1.38
- TXO $14.22
- Analyst Decision
- GERN Buy
- TXO Strong Buy
- Analyst Count
- GERN 7
- TXO 2
- Target Price
- GERN $3.17
- TXO $21.50
- AVG Volume (30 Days)
- GERN 6.7M
- TXO 147.2K
- Earning Date
- GERN 11-06-2025
- TXO 11-04-2025
- Dividend Yield
- GERN N/A
- TXO 16.81%
- EPS Growth
- GERN N/A
- TXO N/A
- EPS
- GERN N/A
- TXO 0.30
- Revenue
- GERN $164,447,000.00
- TXO $332,267,000.00
- Revenue This Year
- GERN $175.15
- TXO $32.89
- Revenue Next Year
- GERN $56.61
- TXO $10.99
- P/E Ratio
- GERN N/A
- TXO $48.23
- Revenue Growth
- GERN 11877.20
- TXO 15.94
- 52 Week Low
- GERN $1.09
- TXO $13.28
- 52 Week High
- GERN $4.50
- TXO $20.70
- Technical
- Relative Strength Index (RSI)
- GERN 44.59
- TXO 56.28
- Support Level
- GERN $1.26
- TXO $14.15
- Resistance Level
- GERN $1.48
- TXO $14.71
- Average True Range (ATR)
- GERN 0.07
- TXO 0.34
- MACD
- GERN -0.00
- TXO 0.06
- Stochastic Oscillator
- GERN 13.64
- TXO 64.71
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America.